ReviewJournal of virology2026
Subtype-specific functions of basal IFNλs.
Review in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type III interferons (IFNλs) represent the newest interferon family, comprising four human subtypes (IFNλ1-4) that signal through the tissue-restricted IFNLR1 receptor. While traditionally characterized as antiviral cytokines protecting mucosal barriers, accumulating evidence suggests that IFNλs possess broader physiological roles that remain incompletely understood. A critical gap in our knowledge concerns whether the four IFNλ subtypes function redundantly, or serve distinct biological purposes. Recent discoveries challenge the assumption of functional redundancy among IFNλ subtypes. Emerging data indicate that different subtypes exhibit distinct signaling kinetics, potencies, and downstream effects on epithelial biology. Beyond their established antiviral functions, IFNλs appear to regulate fundamental aspects of epithelial homeostasis, including barrier integrity, cellular differentiation, and tissue architecture. The discovery of constitutive basal IFNλ expression in healthy epithelia-driven by microbiota and endogenous danger signals-suggests that these cytokines continuously shape tissue physiology rather than functioning solely as inducible defense molecules. Understanding subtype-specific IFNλ functions has become increasingly urgent as these cytokines enter clinical development. The tissue-restricted expression of IFNLR1 offers therapeutic advantages over broadly-acting type I interferons, but optimal clinical application requires comprehensive knowledge of how individual subtypes influence both pathogen control and tissue homeostasis. Critical questions remain: Do specific subtypes preferentially regulate barrier function versus antiviral immunity? Can imbalanced subtype expression contribute to epithelial pathology? How do pathogens differentially induce IFNλ subtypes to evade immunity or promote tissue damage? Addressing these questions will illuminate fundamental principles of mucosal immunity and guide rational design of IFNλ-based therapeutics that maximize protection while preserving epithelial health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.